Bayer Healthcare LLC

Novo Nordisk A/s

Jesper Haaning

Kim Vilbour Andersen

Claus Bornaes

Ole Hvilsted Olsen

Lars Thim

Gert Bolt

Marianne Hjortnes Kjalke

Christian Rischel

Frederik Rode

Kirstine Roepstorff

Maj Petersen

Jens Jacob Hansen

Mads Röpke

Ditte Maria Karpf

Steven Glazer

The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.

Compounds suitable for treatment of haemophilia

Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

Factor VII or Factor VIIa Gla domain variants

Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

Factor V11 or factor V11A GLA domain variants

Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.

FVII or FVIIa variants

The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

Factor VII or VIIa polypeptide variants

Growing community of inventors

Birkeroed, Denmark

Jesper Haaning